NEW YORK (GenomeWeb News) – For the past eight years Menon Biosensors has operated in near secrecy developing a technology with US government backing to detect some of the world's deadliest biothreat pathogens.

Now, the San Diego-based firm is preparing to use that same technology to change the healthcare market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.